Business Context and Reporting Period
This Form 6-K filing by Alterity Therapeutics Limited (formerly Prana Biotechnology Limited) covers the month of April 2019, specifically reporting on events occurring on April 8, 2019. The filing serves as a Notice of Initial Substantial Holder under Section 671B of the Corporations Act 2001.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This document is a regulatory disclosure regarding shareholding structure rather than a financial performance report.
Material Changes
On April 8, 2019, Alterity Therapeutics Limited became a substantial holder of its own voting securities. The company now holds a relevant interest in 288,498,110 fully paid ordinary shares, representing 33.51% of the total voting power. This interest arose from a voluntary escrow under a voluntary restriction agreement with Life Biosciences LLC and lock-up letters regarding shares held by certain directors and the company secretary. No cash or non-cash consideration was paid for this interest.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. The primary disclosure relates to corporate governance and shareholding restrictions. The substantial holding is subject to voluntary restrictions and lock-up agreements, which may limit the immediate tradability of these shares.
Investor Verification Checklist
- Verify the terms of the voluntary restriction agreement between Alterity Therapeutics Limited and Life Biosciences LLC.
- Confirm the specific lock-up conditions applicable to the shares held by directors and the company secretary.
- Review the breakdown of the 288,498,110 shares held in escrow, noting that 269,905,533 are registered to Life Biosciences LLC.
- Check for any subsequent filings regarding the release of these shares from escrow or changes in voting power.